Sniffing around the Lecanemab for Alzheimer's Disease Story and sundry Zum Zum Water Products

Game changers, disease modifiers, breakthroughs, waters of long life and all that.

After the antivirals and Comirnaty stories, we looked at the evidence base of a few amazing interventions paraded by the media. The first was Lecanemab, a monoclonal antibody (MAB) that, according to its manufacturer, Eisai Ltd, attacks amyloid plaques, lowers their burden in the brain, and modifies the course of the earlier stages of the disease. This …